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The complex relationship between the use of antidepressants and suicidal behaviour is one of the hottest topics of our
contemporary psychiatry. Based on the literature, this paper summarizes the author’s view on antidepressant-resistant depression
and antidepressant-associated suicidal behaviour. Antidepressant-resistance, antidepressant-induced worsening of depression,
antidepressant-associated (hypo)manic switches, mixed depressive episode, and antidepressant-associated suicidality among
depressed patients are relatively most frequent in bipolar/bipolar spectrum depression and in children and adolescents. As
early age at onset of major depressive episode and mixed depression are powerful clinical markers of bipolarity and the manic
component of bipolar disorder (and possible its biological background) shows a declining tendency with age antidepressant-
resistance/worsening, antidepressant-induced (hypo)manic switches and “suicide-inducing” potential of antidepressants seem to
be related to the underlying bipolarity.
1. Introduction
Treatment-resistant and particularly antidepressant-resistant
major depression (AD-RD) is a great clinical challenge both
in the cases of unipolar and bipolar depression [1, 2].While it
is well documented that the optimal clinical response to anti-
depressants is much rare in bipolar I and II than in un-
ipolar major depression [3–5] only the most recent clinical
studies have focused on the boundaries between treatment-
resistant unipolar major depressive disorder and bipolar
disorder. These studies seem to be more promising in under-
standing both antidepressant-resistance and antidepressant-
associated suicidal behaviour in patients with major mood
disorders.
2. Antidepressant Resistance in Major
Depressive Episode: Its Relationship with
Bipolar Disorder
The generally accepted definition of AD-RD refers that
the depressed patient does not show a clinically significant
response after at least two adequate trials of diﬀerent
classes of antidepressants. In spite of the fact that there
are several causes of AD-RD in general [1, 6], one of the
most common sources of it is the unrecognized bipolar
nature of the “unipolar” major depressive disorder, when the
patients receive antidepressant monotherapy—unprotected
by mood stabilizers/atypical antipsychotics [4–11]. Unrecog-
nized bipolar depressives are generally treated as “unipolar”
major depressives which means that these patients do not
receive mood stabilizers [3, 12]. This can result in a very high
rate of treatment resistance, which is about two-times higher
than in patients with true unipolar major depression [4–10].
The frequency of AD-RD ranges from 41% to 65% in bipolar
I and II depression and between 18%–27% in unipolar
depression [4–6, 10]. The rate of the bipolar spectrum dis-
order among the DSM-IV defined antidepressant responsive
unipolar major depressive disorder inpatients was 3.8%, but
the same figure in antidepressant-resistant inpatients was
47.1% [6] indicating that the underlying bipolar diathesis
was important contributor to antidepressant nonresponse.
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Antidepressant monotherapy in bipolar and bipolar
spectrum depressives can worsen the cross-sectional pic-
ture of depression not only by resulting in (hypo)manic
switch, but also via inducing or aggravating depressive
mixed state/agitation, that is the major substrate of suicidal
behaviour [7, 13–15]. The retrospective chart-review of 17
patients with “prebipolar” major depression (i.e., patients
who become bipolar I and II during the followup) and
of 17 pure unipolar depression showed that early onset
of major depressive episode as well as treatment-emergent
mixed depression, mood lability, psychomotor activation,
suicidality, and nonresponse to antidepressant monotherapy
were significantly more frequent in “prebipolar” than in pure
unipolar depressives [10]. As early-onset major depression
is a risk factor for bipolar depression [16–18] the higher
frequency of antidepressant-induced mania [19] and the
much lower rate of antidepressant response in children and
adolescents than in adults [20] are also the reflexions of
the bipolar nature of depression in these cases. A study
on antidepressant-associated chronic irritable dysphoria
(ACID) showed that it was significantly more common
among bipolar I and II depressives who received antidepres-
sants than among those who did not receive antidepressants,
and the development of ACID (i.e., worsening of depression)
was significantly related to past history of antidepressant-
induced mood switches [14]. It is also known that bipolar
spectrum and bipolar II depressives have frequently a loss of
response to repeated trials of antidepressants (also called as
tachyphyaxis) before developing chronic and severe AD-RD
[8, 21].
The cross-sectional clinical picture of ACID [9, 14]
is almost identical, with the clinical presentation of the
depressive mixed state (= 3 or more intradepressive none-
uphoric hypomanic symptoms) which is present in about
50%–60% of bipolar II depressives and around 20%–30%
of unipolar depressives [22–27]. Family history data, demo-
graphic variables as well as long-term course, indicate
that depressive mixed state, even in the frame of unipolar
depression belongs to the broader bipolar spectrum [22–
25, 28–30]. The recognition of depressive mixed state has
important practical implications as several studies have
shown that compared to pure major depressive episode the
risk of suicidal behaviour is markedly elevated in mixed
depressive episode both in DSM-IV diagnosed unipolar and
bipolar depression [13, 22, 27, 31–34].
DSM-IV-defined unipolar major depressive disorder
patients with subthreshold bipolarity convert more often
into DSM-IV bipolar disorders than those with pure (unipo-
lar) major depressive disorder [12], and maniform mood
switches during antidepressant pharmacotherapy are signif-
icantly more common in bipolar than in unipolar depres-
sion. In addition, agitated/mixed major depression (even
minimal hypomanic symptoms coexisting with otherwise
full syndromal major depression) significantly predicts man-
iform switches during antidepressant treatment in patients
with bipolar I and II depression [4, 6, 29, 35]. Because
antidepressant-induced mood switch can be markedly
reduced by coadministration of lithium or other mood
stabilizers [4, 36–39] and antidepressant-induced worsening
of depression (i.e., ACID) is significantly related to prior
mood switches [14] it is very likely that co-administration
of lithium/other mood stabilizers with antidepressants can
reduce the risk not only of the (hypo)manic switch, but
also of drug-resistance as well as developing AD-RD or
worsening of depression in manifest or covert cases of
bipolar depression. The well-documented positive eﬀect
of lithium (and atypical antipsychotic) augmentation in
antidepressant-resistant unipolar major depressive disorder
[1] and the marked antisuicidal eﬀect of lithium in bipolar
and unipolar mood disorder patients [40] also supports this
postulation. The high rate of responders and remitters in
patients receiving quetiapine monotherapy both in DSM-
IV unipolar and bipolar depression [41, 42] also suggests
that the antidepressant-resistance of these patients might
be causally related, at least in part, to the underlying
(hypo)manic component of the depressive episode.
3. Antidepressants and Suicidal Behaviour:
The Role of Underlying Bipolarity
This phenomenon of AD-RD and antidepressant-induced
mood switch is also related to “antidepressant-induced
suicidal behaviour.” As suicidality decreases/vanishes after
clinical recovery of depression, nonresponse to antidepres-
sants or worsening of depression due to antidepressants or
spontaneous worsening is an important suicide risk factor
[33, 48]. Themeta-analysis of the eﬃcacy of SSRIs in children
and adolescents with major depressive disorder showed that
the rate of responders was significantly higher in patients
receiving fluoxetine and citalopram/escitalopram than those
receiving placebo, but there was no significant drug-placebo
diﬀerence for patients receiving paroxetine and sertraline.
In line with this, the relative risk of “antidepressant-
associated” suicidal behaviour (attempts and ideations only)
was much lower in fluoxetine and citalopram/escitalopram
patients than in paroxetine and sertraline groups [43]. The
rarely occurring antidepressant-associated suicidality among
depressed patients is relatively most frequent in children
and adolescents and less common in middle-aged persons
and in the elderly both in RCTs [44–46] and observational
studies [47]. As early age at onset of major depressive episode
is a powerful clinical marker of bipolarity [16–18], and
the manic component of bipolar disorder (and possible its
biological background) shows a declining tendency with age
[30]. The “suicide-inducing” potential of antidepressants,
occurring almost exclusively among young patients, seems
to be really related to the underlying bipolarity. This is
supported by the finding that mixed major depressive
episode—a well-considered suicide risk factor—is much
more frequent in children and adolescents than in adults
[49]. As combination of antidepressants andmood stabilizers
reduces the “iatrogenic” hypomanic/manic mood switch
[4, 29, 37–39] this treatment strategy could be also useful
in avoiding both AD-RD and “antidepressant-associated”
suicidal behaviour. This is important, because a significant
part (30–40%) of DSM-IV diagnosed unipolar depressives
really have subthreshold bipolar II or bipolar spectrum
disorder [3, 12, 24, 25, 30] that means that about one-third
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Table 1: The role of underlying bipolarity in antidepressant-resistance and antidepressant-associated suicidality in patients with mood
disorders.
The frequency of antidepressant-resistance is about double in bipolar (I + II) and bipolar spectrum disorder than in unipolar
depression [4–6, 10]
Antidepressant monotherapy can worsen the cross-sectional picture and long-term course of bipolar (I + II) and bipolar spectrum
disorder [7, 9, 10, 13–15]
Early-onset major depressive episode is (pre)bipolar [16–18, 30]
Children and adolescents with major depressive episode are less
responsive to antidepressants than adults [20, 43]
The rarely occurring antidepressant-associated suicidal behavior
among depressed patients is relatively most frequent in children
and adolescents [43–47]
of DSM-IV diagnosed unipolar depressives are really bipolar
depressives.
As antidepressants can worsen depression but it is
not the case for placebo, this new view can explain why
antidepressant-induced suicidal behaviour is more common
among patients treated with antidepressants compared to
those who receive placebo in Randomized Controlled Trials
(RCTs) on antidepressant monotherapy in unipolar major
depression: subthreshold bipolar depressives and bipolar
spectrum depressives (including agitated depressives and
depressed patients with family history of bipolar disorder)
are not excluded from this trials resulting in a significant part
of bipolar depressives among this study population [12, 30].
If the depression worsening and suicidal behaviour-
inducing potential of antidepressants are largely limited for
depressive patients only, particularly for those with overt or
covert bipolar depression, no worsening of general condition
or no depression-provoking eﬀect and no increased suici-
dality in patients receiving antidepressants for other than
depression indication would be expected. Indeed, the meta-
analysis of 372 placebo-controlled randomised antidepres-
sant trials showed that, for participants with nonpsychiatric
indications (N = 22, 024), suicidal behaviour is extremely
rare and consisted almost entirely of suicidal ideation alone
[46]. A most recent analysis of almost 15,000 patients from
57 placebo-controlled paroxetine trials on major depressive
disorder and anxiety disorder showed no diﬀerences between
paroxetine and placebo for suicidal behaviour. However,
in the separate analysis of patients with major depressive
disorder, the incidence of suicidal behaviour was significantly
greater for paroxetine than for placebo (0.32% versus 0.05%,
OR = 6.7) particularly among young adults aged 30 years
or less. On the other hand, in the nondepression clinical
trial database (N = 8931) the rates of suicidal behaviour in
the paroxetine group and in the placebo group were almost
identical (0.13% and 0.11%, resp.) [45].
Worsening of medical state, in which the given drugther-
apy is eﬀective in general, but could at times be problematic,
is also a problem in other fields of medicine. Provocation of
a new arrhythmia or increase in the frequency of preexisting
arrhythmia occurs with all antiarrhythmic drugs in 6%–23%
of cases, particularly among those patients with underlying
heart disease and evidence of ongoing overt or salient cardiac
ischemia. As a rule, aggravation of arrhythmia occurs mainly
in the first few days of initiating therapy but occurrence of a
new arrhythmia can also be a late complication of it [50, 51].
4. Conclusions
There is no doubt that successful acute and long-term
antidepressant pharmacotherapy of depressive patients sig-
nificantly reduces the risk of suicidality in the vast majority
of patients but antidepressant monotherapy (unprotected
by mood stabilizers or atypical antipsychotics) is frequently
ineﬀective and rarely can worsen bipolar depression and
therefore increase the suicide risk in a small, vulnerable
subpopulation of them. Antidepressants cannot “cause”
suicidal behaviour but, as discussed above, in contrary to
placebo, they can worsen depression. As suicidality in
depressed patients is also severity-dependent phenomenon
worsening of depression is the main final “cause” of suicidal
behaviour even in drug-free depressives. When antidepres-
sant monotherapy worsens depression (and consequently
increases the suicide risk) in relatively few patients, its
psychopathological substrate might well reside in an agitated,
excited, mentally overstimulated depressive mixed state that
arises primarily from the underlying bipolar diathesis (see
Table 1). The pattern the clinical response to antidepressant
monotherapy in major depressive episode seems to be lied is
on a continuum, the diﬀerent steps of which are (1) optimal
response (response/remission), (2) no significant change,
(3) worsening of depression (covert switch = occurrence
of intradepressive hypomanic symptoms = antidepressant-
induced depressive mixed state), and (4) hypomania or
mania (overt switch). Psychiatrists should identify persons
who might be not helped or threatened by a given inter-
vention. The formal recognition of subthreshold bipolar
(bipolar spectrum) disorders, particularly of depressive
mixed states, in our oﬃcial diagnostic systems will help to
identify those depressives who do not respond/worsen to
antidepressant monotherapy and consequently they are at
increased risk of suicidal behaviour [15, 22]. Incorporating
these new findings into everyday clinical practice is urgently
needed.
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